文献速递生殖医学

促性腺激素受体多态性(FSHR N680S 与 LHCGR N312S)不能预测辅助生殖技术中的临床结局与活产

Gonadotropin receptor polymorphisms (FSHR N680S and LHCGR N312S) are not predictive of clinical outcome and live birth in assisted reproductive technology.
PubMed 文献 · Fertil Steril · 2022-07-13

回顾性队列研究纳入2006至2017年首次接受辅助生殖技术并做非整倍体筛查的18-40岁女性1183例,检测FSHR N680S与LHCGR N312S基因型,分析其与活产等结局的关联。按受体单独或联合分析,各基因型与卵母细胞产出、可用囊胚率、种植率及活产均无显著关联;仅不同变异组合间成熟卵母细胞率存在统计学显著但临床无关的差异。作者认为这些变异不应被视为生殖预测指标。

要点

  • FSHR N680S与LHCGR N312S各基因型与活产、种植率、可用囊胚率均无显著关联。
  • 不同变异组合间成熟卵母细胞率有统计学显著但临床无关的差异。
  • 作者认为这些变异不应作为辅助生殖技术的生殖预测指标。

核心结论

  • 作者认为FSHR N680S与LHCGR N312S多态性与辅助生殖技术结局无关联,不应被视为生殖预测指标。

研究设计与样本

  • 回顾性队列研究,纳入2006至2017年在私立生殖门诊首次接受辅助生殖技术并做非整倍体筛查的18-40岁、体重指数>18且<40 kg/m2的女性。
  • 共1183例患者符合纳入标准并获得可靠基因型结果,所有患者均接受重组卵泡刺激素联合人绝经期促性腺激素或低剂量人绒毛膜促性腺激素。
  • 从患者血液提取基因组DNA,用TaqMan基因分型法检测FSHR与LHCGR多态性,采用广义回归与方差分析评估基因型与临床结局的关联。

主要发现

  • 研究人群中FSHR基因型频率为:680位点S纯合21.7%、N680纯合29.2%、杂合(N680S)48.1%。
  • LHCGR基因型频率为:N312纯合15.6%、S312纯合38.5%、杂合(N312S)45.9%。
  • 研究人群种族构成为非西班牙裔白人53.8%、西班牙裔白人6.1%、非裔美国人4.1%、亚洲人15.4%、其他或未知20.6%。
  • 按受体单独或联合分析基因型时,卵母细胞产出、可用囊胚率、种植率、活产均无显著关联。
  • 不同变异组合间成熟卵母细胞率存在统计学显著但临床无关的差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the consequences of specific genotype profiles of follicle-stimulating hormone receptor (FSHR) and luteinizing hormone choriogonadotropin receptor (LHCGR) on assisted reproductive technology outcomes when preimplantation genetic testing for aneuploidy is used for controlling the embryo ploidy status. The most common reported single-nucleotide polymorphisms in the amino acid position for the FSHR (N680S; N: asparagine, S: serine; [rs6166]) and the LHCGR (N312S variant; N: asparagine, S: serine [rs2293275]) were chosen for this study. DESIGN: Retrospective cohort study. SETTING: Private Fertility Clinic. PATIENT(S): All women aged 18-40 years undergoing their first assisted reproductive technology cycle with aneuploidy screening between 2006 and 2017 with body mass index of >18 and <40 kg/m2 were included. INTERVENTION(S): All patients received both recombinant follicle-stimulating hormone and human menopausal gonadotropin or low dose human chorionic gonadotropin. Genomic DNA was isolated from patients' blood. Genotyping of the FSHR and LHCGR polymorphisms was performed using TaqMan genotyping assays. Associations between both receptor genotypes and clinical outcomes were assessed using generalized regression and ANOVA. MAIN OUTCOMES MEASURE(S): Live birth rate was the primary outcome. Secondary outcomes included oocyte yield, mature oocytes, blastulation rate, usable blastocyst rate, and implantation rate. RESULT(S): A total of 1,183 patients met the inclusion criteria and generated reliable genotype results. The overall genotype frequencies in the study population for the FSHR gene were as follows: 21.7% homozygous for S in codon 680, 29.2% homozygous for N680, and 48.1% heterozygous (N680S). As for the LHCGR, 15.6% were homozygous for N312, 38.5% homozygous for S312 and 45.9% heterozygous (N312S). Our study population consisted of 53.8% non-Hispanic white; 6.1% Hispanic white; 4.1% Afro-American; 15.4% Asian; and 20.6% other or unknown. No significant association was found with any of the studied variables (oocyte yield, usable blastocyst rate, implantation rate, live birth) when genotypes were analyzed per receptor or in combination with one another. There was a statistically significant but clinically irrelevant difference in the rate of mature oocytes across different variant combinations. CONCLUSION(S): Our findings suggest that the presence of gonadotropin receptor polymorphisms in both FSHR N680S and LHCGR N312S are not associated with assisted reproductive technology outcomes; therefore, these variants should not be considered reproductive predictors.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Pirtea P, de Ziegler D, Marin D, et al. Gonadotropin receptor polymorphisms (FSHR N680S and LHCGR N312S) are not predictive of clinical outcome and live birth in assisted reproductive technology. Fertil Steril. 2022. PMID: 35842313. doi:10.1016/j.fertnstert.2022.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。